EyeQDirectory

Official company dossier

Eisai Co., Ltd.

AI Expert

Pharmaceutical Companieseisai.comUS

AI Trust Score, Reviews & Company Verification

Ownership opportunity

Is this your company? Claim the Eisai Co., Ltd. profile to verify ownership and manage company-provided details.

Independent company assessment

9.0/10A · Exceptional

35 indexed evidence signals reviewed

AI Comparison

Mixed Consensus69% Confidence

Based on 8 polled AI models

  • GPT-5.6OpenAI
    Mixed78%Confidence
  • ClaudeAnthropic
    Mixed65%Confidence
  • GeminiGoogle DeepMind
    Mixed75%Confidence
  • GrokxAI
    Mixed70%Confidence
Updated Sep 8
Profile not verified by the brand
Unclaimed profile

This profile is waiting for Eisai Co., Ltd.

Eisai Co., Ltd. has not claimed this ShouldEye profile yet.

Until an authorized representative verifies ownership, ShouldEye AI independently maintains this overview from public records, reviews, regulatory filings, and live trust signals. Nothing on this page has been approved by the brand.

AI-maintained · Not brand-verified

  • Respond to reviews and experiences in your voice
  • Replace this placeholder with your official brand message
  • Take control of how your trust score is presented

Free verification for authorized company representatives

About

Eisai Co., Ltd. is a Japanese research‑based pharmaceutical company that focuses on oncology and neurology, including dementia‑related diseases, and operates globally.

Headquarters
US
EyeQ
EyeQ AI Live

Full intelligence report for Eisai Co., Ltd.

High confidence

Eisai demonstrates strong operational accountability through rigorous regulatory compliance, a well-regarded reputation, and responsive customer service, all of which reinforce its verified trust standing. Its privacy and advertising practices meet solid standards, though a comparatively weaker domain integrity score reveals a gap in digital infrastructure resilience that stands out from the otherwise strong profile. Overall, these signals portray a highly trustworthy organization with robust governance, but strengthening its domain protections would further solidify its consumer-facing reliability.

Strengths
  • Clear categorization of data collection and usage for patients and healthcare professionals in privacy policy
  • Explicit opt‑in consent mechanisms for sensitive data with revocation process
  • Dedicated Data Protection Officer and GDPR/UK representatives with accessible contact information
Key Risks
  • Vague data retention periods, creating risk of indefinite storage
  • No explicit disclosure of personal data use for AI/ML model training
  • Absence of clear data breach notification procedures
Domain & infrastructure
Key-Systems GmbHDomain registrar
—Domain age
3 assetsVerified assets
Contact & Support
People Behind Eisai Co., Ltd.

Public-facing leadership and ownership signals for Eisai Co., Ltd. — synthesized from verified profiles and corporate disclosures where available.

T
Tatsuyuki Yasuno
Chairman & Chief Executive Officer (CEO)
H
Haruo Naito
Global Chief Executive Officer (CEO)
B
Brian Harraka
Chief Financial Officer (CFO)
L
Lynn Kramer
Chief Clinical Officer
S
Sayoko Sasaki
Vice President
S
Shohei Kanazawa
President, East Asia Global South Region
T
Toshitaka Asano
Vice President, Business Development
M
Makoto Hoketsu
Chief Information Officer (CIO)
T
Toshihiko Yusa
Vice President, Japan Business
K
Katsutoshi Ido
Chief Scientific Officer (CSO)
T
Takuya Oyama
Chief Financial Officer (CFO)
Y
Yanhui Feng
Chairman, Eisai China Holdings Ltd.
S
Shin Kato
General Counsel